Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management

May 16th 2025

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer

May 16th 2025

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer

May 16th 2025

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025

May 16th 2025

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Dr Hall on Unmet Needs in Later-Line RCC

May 15th 2025

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

May 15th 2025

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Dr Sabari on the Activity of Zongertinib in Pretreated, Advanced, HER2-Mutated NSCLC

May 15th 2025

Joshua K. Sabari, MD, discusses how phase 1 efficacy data with zongertinib in HER2-mutant NSCLC lay the foundation for future research with the agent.

Dr LeVee on Ongoing Research With Immunotherapy and ADCs in TNBC

May 15th 2025

Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.

Dr Eskander on Interpreting Biomarker Analyses From the DUO-E Trial in pMMR Endometrial Cancer

May 15th 2025

Ramez N. Eskander, MD, discusses the limitations of biomarker analyses for guiding treatment decisions in pMMR endometrial cancer.

Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination

May 14th 2025

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

May 14th 2025

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

May 14th 2025

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer

May 13th 2025

Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.

Dr Bhat on the Limitations of Current Treatments for Double-Refractory CLL

May 12th 2025

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Dr Tarantino on Early-Stage HER2+ Breast Cancer Risk Stratification

May 12th 2025

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Dr Wagar on the Use of T-DXd in Patients With HER2+ Endometrial Cancer

May 9th 2025

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Dr Fenske on Assessing the Role of Auto-HCT in the Current MCL Treatment Paradigm

May 9th 2025

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

May 9th 2025

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Novel STAT3 Inhibitor TT1-101 Is Safe and Shows Antitumor Activity in R/R HCC and Other Solid Tumors

May 9th 2025

The STAT3 inhibitor TT1-101 generated confirmed partial responses among patients with relapsed/refractory HCC and other solid tumors.

Dr Uboha on the Role of Biomarkers for Guiding Esophageal Adenocarcinoma Treatment Selection

May 8th 2025

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.